Méndez-Martínez et al. found that MEK1 inhibitors for the treatment of metastatic BRAF-mutant cutaneous melanoma and NRAS mutant melanoma were ground-breaking therapeutic regimens, respectively12. The gene discussed is MAP2K1; the disease is melanoma.